Your session is about to expire
← Back to Search
Dietary Supplement
XS Muscle Multiplier for Sarcopenia
N/A
Waitlist Available
Led By David D Church, Ph.D.
Research Sponsored by University of Arkansas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Ages 18 - 30 and 70-89 yrs
For the sarcopenic group, a SARC-F score of ≥ 4 at the screening visit
Timeline
Screening 3 weeks
Treatment Varies
Follow Up a 5-hour period.
Awards & highlights
Study Summary
This trial will test if a new way of measuring muscle health is accurate. The results could help doctors learn about muscle health before patients experience a loss of function.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ a 5-hour period.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~a 5-hour period.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Maximum plasma leucine concentration.
Trial Design
1Treatment groups
Experimental Treatment
Group I: 10g of nutritional productExperimental Treatment1 Intervention
All subjects will ingest 10g of a commercially available nutritional supplement one time during a study visit.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
XS Muscle Multiplier
2022
N/A
~30
Find a Location
Who is running the clinical trial?
University of ArkansasLead Sponsor
485 Previous Clinical Trials
149,843 Total Patients Enrolled
8 Trials studying Sarcopenia
188 Patients Enrolled for Sarcopenia
David D Church, Ph.D.Principal InvestigatorUniversity of Arkansas
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger